A

new analysis finds that a notable portion of treatment guidelines issued in recent years by medical societies and government agencies for combating mild depression were compiled by individuals with financial conflicts of interest or lacked other safeguards to ensure impartiality.

Of 172 people who participated in 14 guidelines committees, 18 percent had ties to drug makers that sell antidepressants, and some had connections to more than one company. Five guidelines, meanwhile, recommended antidepressants as a first-line treatment for mild depression, and four of those — or 80 percent — had panelists with some type of financial connection, according to the analysis in Psychotherapy and Psychosomatics.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Most antidepressants are prescribed by primary care physicians most of whom don’t know the first thing about psychopharmacology. The patients often wind up seeing the shrink due to medication mismanagemen by the idiot GP who produces an iatrogenic serotoninergic crisis because they were unaware of the taper guidelines for SSRI’s.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.